Rewiring Addiction: Psychedelic Therapy from Brain Circuits to Lived Recovery
This symposium offers a comprehensive exploration of the therapeutic potential and novel and emerging mechanisms of action of psychedelic therapy in addressing addiction. We will cover lab-based studies through to patient perspectives, offering a multidisciplinary and integrated overview of the latest findings coming from ongoing psychedelic therapy for addiction studies to help inform and inspire the next phase of research and implementation.
Presentations will delve into three clinical studies being conducted at Imperial College London, University College London and Exeter University.
From Imperial, we will cover two studies, examining the clinical efficacy and novel multimodal biomarkers of psychedelic therapy in treating gambling and opioid addiction.
University College London, the UNITY project, which focuses on naturalistic neuroimaging and behavioural psychopharmacology approaches, specifically focusing on DMT (N, N-Dimethyltryptamine) for heavy drinking.
Exeter University will provide the latest patient-perspective research from the MORE-KARE Ketamine assisted therapy for AUD phase III clinical trial.
By bringing together clinical studies, neuroimaging research, and theoretical frameworks, the symposium promises to advance our understanding of psychedelic therapy's potential in combating addiction and offer new avenues for treatment development.
